Mark A. Socinski, MD
Executive Medical Director,
Florida Hospital Cancer Institute,
Orlando, Florida
Join Dr. Socinski as he uses a case-based approach to highlight the importance of biomarker-driven clinical decision making in advanced non-small cell lung cancer (NSCLC), and reviews best practices for optimizing biomarker testing.
CASE STUDY ON BIOMARKER TESTING IN ADVANCED NSCLC
Case Study
Patient Case: Biomarker Testing in Advanced NSCLC
Chung-Che (Jeff) Chang, MD, PhD
A Case-Based Pathology Perspective on Biomarker Testing in NSCLC
Gaetane C. Michaud, MD
A Case-Based Pulmonology Perspective on Biomarker Testing in NSCLC
Mark A. Socinski, MD
A Case-Based Oncology Perspective on Biomarker Testing in NSCLC
IN ADVANCED NSCLC
Chung-Chee (Jeff) Chang, MD, PhD
A Pathology Perspective on Biomarker Testing in NSCLC
Martin Dietrich, MD, PhD
A Community Oncology Perspective on Biomarker Testing in NSCLC
Gaetane C. Michaud, MD
A Pulmonology Perspective on Biomarker Testing in NSCLC
Mark A. Socinski, MD
An Oncology Perspective on Biomarker Testing in NSCLC
